269 related articles for article (PubMed ID: 28122957)
1. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Qu J; Sun W; Zhong J; Lv H; Zhu M; Xu J; Jin N; Xie Z; Tan M; Lin SH; Geng M; Ding J; Huang M
J Cell Biol; 2017 Feb; 216(2):409-424. PubMed ID: 28122957
[TBL] [Abstract][Full Text] [Related]
2. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
3. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
5. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
6. CtIP-mediated resection is essential for viability and can operate independently of BRCA1.
Polato F; Callen E; Wong N; Faryabi R; Bunting S; Chen HT; Kozak M; Kruhlak MJ; Reczek CR; Lee WH; Ludwig T; Baer R; Feigenbaum L; Jackson S; Nussenzweig A
J Exp Med; 2014 Jun; 211(6):1027-36. PubMed ID: 24842372
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.
Sivanand S; Rhoades S; Jiang Q; Lee JV; Benci J; Zhang J; Yuan S; Viney I; Zhao S; Carrer A; Bennett MJ; Minn AJ; Weljie AM; Greenberg RA; Wellen KE
Mol Cell; 2017 Jul; 67(2):252-265.e6. PubMed ID: 28689661
[TBL] [Abstract][Full Text] [Related]
8. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
11. A role for human homologous recombination factors in suppressing microhomology-mediated end joining.
Ahrabi S; Sarkar S; Pfister SX; Pirovano G; Higgins GS; Porter AC; Humphrey TC
Nucleic Acids Res; 2016 Jul; 44(12):5743-57. PubMed ID: 27131361
[TBL] [Abstract][Full Text] [Related]
12. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
Zimmer J; Tacconi EMC; Folio C; Badie S; Porru M; Klare K; Tumiati M; Markkanen E; Halder S; Ryan A; Jackson SP; Ramadan K; Kuznetsov SG; Biroccio A; Sale JE; Tarsounas M
Mol Cell; 2016 Feb; 61(3):449-460. PubMed ID: 26748828
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of anthraquinone derivatives as allosteric phosphoglycerate mutase 1 inhibitors for cancer treatment.
Huang K; Jiang L; Liang R; Li H; Ruan X; Shan C; Ye D; Zhou L
Eur J Med Chem; 2019 Apr; 168():45-57. PubMed ID: 30798052
[TBL] [Abstract][Full Text] [Related]
14. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks.
Caron MC; Sharma AK; O'Sullivan J; Myler LR; Ferreira MT; Rodrigue A; Coulombe Y; Ethier C; Gagné JP; Langelier MF; Pascal JM; Finkelstein IJ; Hendzel MJ; Poirier GG; Masson JY
Nat Commun; 2019 Jul; 10(1):2954. PubMed ID: 31273204
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
[TBL] [Abstract][Full Text] [Related]
20. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
